Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography - Wikidata - wikimedia - TriplyDB

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

http://www.wikidata.org/entity/Q28354052

about

Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature Review Prognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysis The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.Visualization, imaging and new preclinical diagnostics in radiation oncology.NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients.Positron Emission Tomography (PET) in Oncology From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.18F-FDG PET/CT imaging in oncology Positron emission tomography in cancer research and treatment.18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.The role of PET and PET-CT scanning in assessing response to neoadjuvant therapy in esophageal carcinoma Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients?Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation.18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.PET/CT and hepatic radiation injury in esophageal cancer patients.Positron emission tomography: clinical applications in oncology. Part 1.The contribution of PET/CT to improved patient management.Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.Role of positron emission tomography in the (re-)staging of oesophageal cancer.(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.Functional PET imaging in cancer drug development.Response evaluation after neoadjuvant chemoradiation by positron emission tomography-computed tomography for esophageal squamous cell carcinoma.PET/CT in oncology: for which tumours is it the reference standard?The role of positron emission tomography in esophageal cancer.The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer.Clinical usefulness of 18F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapy Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.Role of barium esophagography in patients with locally advanced esophageal cancer: evaluation of response to neoadjuvant chemoradiotherapy.PET imaging for Treatment Response in Cancer Timing and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy.Role and cost effectiveness of PET/CT in management of patients with cancer.Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis.Endoscopic management of esophageal cancer after definitive chemoradiotherapy.

P2860

Q26777898-AC051975-D1A4-47F2-9B17-189EA5074B4E Q28081159-87EAC0D7-C101-4184-84F4-33CBA16F20F6 Q30393722-664CD332-2F7C-4FC6-A8F4-C5B5A7E3E214 Q30725740-D9C42C53-F27E-4786-8797-DBFD9CFC73B3 Q33356751-2BFF575B-D249-41CB-A05C-8751D9D2042E Q34023973-948748E2-F060-42B0-81C3-00F36578E5F2 Q34104159-EC345CFB-A982-4930-A712-A18E0C6F1B6B Q34298027-78917049-B331-4AE8-BCBD-101871F7F310 Q34390923-A9BD65CC-F01D-4D31-8944-5A73A70A5DB3 Q34521659-BF6B15DE-F8B7-4E9E-B45B-5EDCD59B0DC0 Q34774840-FC6D0762-FD65-4468-8EF4-27CD68C1ADE5 Q34978457-F757E777-6B96-4428-AA09-75D1FCA96DFD Q35006097-487A7ABE-CF0D-467E-8708-36269910DE55 Q35081118-EFD109B7-1462-4572-97C3-52013DFB0C8A Q35127213-09CB07D5-ADE0-4141-B1AB-0B15330E2547 Q35769322-30275166-57FB-45A4-9DE9-865C95D43233 Q35824736-4777AECE-C091-4481-A6E0-E5C635E22B7E Q36022348-51119BAA-CDB3-40CA-88A4-3B271DCFED56 Q36201687-79A95264-6E35-414E-A52F-4D7D7A8F2DCD Q36295210-77E8FF8D-0BD0-40FE-8689-C7E2EFBF122B Q36334917-CD24C81C-BF51-4F9C-BA91-6CED1A44B155 Q36371912-FF9B6195-AA06-4CF7-91B4-6DC2DCDE1AC0 Q36427789-372B2E3B-5730-4FB4-83E6-EFB2FFA7D535 Q36510702-9B487648-9FB1-4064-8767-66053E54F768 Q36611842-C1286B9D-39E4-4AAC-BDE2-5C85D19BB41E Q36626093-14867157-FDA7-417D-AE14-043C0EBDB900 Q36768305-43B1BC65-9847-48DD-8884-D5E0B42CF54D Q36775121-6D866CEB-C3E6-43EC-9089-3D680FF725F1 Q36963748-A99AD55E-47BF-4C32-8F07-02180E46633D Q37072481-95D6ED9C-0D21-4729-8C2D-70E18F76C7A1 Q37076617-8B8A4282-B522-41FF-A23D-63EC2DA3B9AF Q37161611-189B74B3-AC79-4CBE-AB26-F5C087D23224 Q37342399-AFF27521-06CB-4E79-8298-F907AE3FE548 Q37348247-ED4DD5E7-D979-4455-99D2-4C7A08BFC8DD Q37402817-B2ACDC51-20A5-43EB-99E6-F3EB8743E2F5 Q37465205-5F83EF94-5845-4C51-8E38-CF2099447445 Q37717566-807A19AE-4B39-4E9B-A850-7EB9C6C9EB0C Q37768682-F8D5DE39-9FEC-4584-8DF1-0A1256D27D5E Q37984273-3AE402AC-35E2-4461-AE60-30A9AC8C2627 Q38074582-A1415D4D-D35F-44D8-AEAA-B5315385FC69

P2860

Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography

http://www.wikidata.org/entity/Q28354052

description

2001 nî lūn-bûn

@nan

2001 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մարտին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Neoadjuvant therapy of esophag ...... y positron emission tomography

@ast

Neoadjuvant therapy of esophag ...... y positron emission tomography

@en

Neoadjuvant therapy of esophag ...... y positron emission tomography

@nl

type

label

Neoadjuvant therapy of esophag ...... y positron emission tomography

@ast

Neoadjuvant therapy of esophag ...... y positron emission tomography

@en

Neoadjuvant therapy of esophag ...... y positron emission tomography

@nl

prefLabel

Neoadjuvant therapy of esophag ...... y positron emission tomography

@ast

Neoadjuvant therapy of esophag ...... y positron emission tomography

@en

Neoadjuvant therapy of esophag ...... y positron emission tomography

@nl

P1433

Q28354052-02E83AAC-E5A9-49A4-B8BA-5E72FD543C50

P1476

Q28354052-8E77A200-BA8B-4A46-A8DB-F1B00234FEB5

P2093

Q28354052-09D42716-1397-4DA8-8939-40E155FA84F1

Q28354052-161A73BA-6D7A-42DB-A6E0-2B2CCABFA4F2

Q28354052-5F6831EF-0BBE-4E42-A28A-9B1EA5280F85

Q28354052-6FDD37DB-4300-454F-9562-D8D6A19428B3

Q28354052-9C7BA389-5C69-4EA6-94F5-35FACA85DF60

Q28354052-D6F8254C-434E-4BC6-95D8-3C765113996D

Q28354052-D97DD339-B6CD-48C3-88FE-704523631B0B

Q28354052-E4A77454-AE2F-4ADD-A55C-2C3ED2062809

Q28354052-EAEA7CA2-F285-4EAF-ABCB-9CC1952AC10E

P2860

Q28354052-05E8F8B4-F203-4207-801A-3F0076C6E513

Q28354052-08581210-B892-4B61-98C2-59F3D24EA51C

Q28354052-1E3AFBE2-ABD6-4D70-ACDB-2ED7552698F6

Q28354052-29C3C305-1EEB-47B2-A69F-BFA567F82B13

Q28354052-31B6BE99-76E0-427D-93AB-B6E85AA29FA2

Q28354052-46DA32BC-025A-4444-9AFC-74C054BC208B

Q28354052-599F1CFC-EE2B-4212-8D0A-76C00AF89103

Q28354052-71EE92A9-67E5-491D-8922-112D86B6C688

Q28354052-8A839531-6732-4810-9102-B63EA8D75F12

Q28354052-92B16E9E-40C4-4A52-9BB6-AE0E540A3A62

P304

Q28354052-84105519-D601-40A9-AAD5-873C71A1CBEF

P31

Q28354052-9C54499F-9222-4A44-97C1-FD3E706D60F6

P3181

Q28354052-1FD5BC2F-2B23-4542-B0D1-8D1B377776D6

P356

Q28354052-BA480700-1516-47A8-9115-498A0415F2D5

P407

Q28354052-EBF9E3CD-5861-401E-8899-1E889504AE9E

P433

Q28354052-A56A821A-CE60-42D4-9238-BA1260278092

P478

Q28354052-54694BBB-D6B3-4D03-BB29-41F2BF13BEC5

P50

Q28354052-05198EEC-6833-4CEE-965A-E956AED86BAD

P577

Q28354052-8736235A-6D93-41E4-9951-3D3267EB5176

P5875

Q28354052-72AC7D83-C410-40D9-8AEF-A570A2A737A7

P698

Q28354052-F24C3655-C5E3-4837-AEBF-2A9302D4F06D

P932

Q28354052-DD40693A-C3EE-4CA4-BDB8-50FF0C77F573

P3181

P356

00000658-200103000-00002

P1433

Annals of Surgery

P1476

Neoadjuvant therapy of esophag ...... y positron emission tomography

@en

P2093

F Zimmerman

http://www.w3.org/2001/XMLSchema#string

H J Stein

http://www.w3.org/2001/XMLSchema#string

J R Siewert

http://www.w3.org/2001/XMLSchema#string

M Bauer

http://www.w3.org/2001/XMLSchema#string

M Schwaiger

http://www.w3.org/2001/XMLSchema#string

M Werner

http://www.w3.org/2001/XMLSchema#string

N Avril

http://www.w3.org/2001/XMLSchema#string

U Fink

http://www.w3.org/2001/XMLSchema#string

W Weber

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Reporting results of cancer treatment

Relevance of positron emission tomography (PET) in oncology.

Positron emission tomography for staging of oesophageal and gastroesophageal malignancy

Current strategy in surgery for esophageal cancer.

The applications of PET in clinical oncology.

Surgery for carcinoma of the esophagus.

Multimodal treatment for squamous cell esophageal cancer.

Neoadjuvant therapy for squamous cell esophageal carcinoma.

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

P304

300-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5014883

http://www.w3.org/2001/XMLSchema#string

P356

10.1097/00000658-200103000-00002

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

233

http://www.w3.org/2001/XMLSchema#string

P50

Björn Brücher

P577

2001-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12106085

http://www.w3.org/2001/XMLSchema#string

P698

11224616

http://www.w3.org/2001/XMLSchema#string

P932

1421244

http://www.w3.org/2001/XMLSchema#string